Previous researches in transcriptome and proteome have demonstrated that TP53 mutation exists broadly in patients suffering tumors, such as urothelial carcinoma of the bladder (Xu et al., 2022), lung cancer (Chen and Roumeliotis, 2020; Gillette et al., 2020), and mutant p53 (hereafter referred to as “mutp53”) always results in poor prognosis (Cao et al., 2021). Here, TP53 is linked to bladder transitional cell carcinoma.